Gad A Marshall1, Natacha Lorius1, Joseph J Locascio2, Bradley T Hyman2, Dorene M Rentz1, Keith A Johnson3, Reisa A Sperling1. 1. Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA Massachusetts Alzheimer's Disease Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. 2. Massachusetts Alzheimer's Disease Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. 3. Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA Massachusetts Alzheimer's Disease Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Abstract
BACKGROUND: Impairment in instrumental activities of daily living (IADL) heralds the transition from mild cognitive impairment (MCI) to dementia and is a major source of burden for both the patient and caregiver. OBJECTIVE: To investigate the relationship between IADL and regional cortical thinning and cerebrospinal fluid (CSF) Alzheimer's disease (AD) biomarkers cross-sectionally and longitudinally in clinically normal (CN) elderly, MCI, and mild AD dementia subjects. METHODS: Two hundred and twenty nine CN, 395 MCI, and 188 AD dementia subjects participating in the Alzheimer's Disease Neuroimaging Initiative underwent baseline magnetic resonance imaging, baseline lumbar puncture, and clinical assessments, including the Functional Activities Questionnaire used to measure IADL, every 6 to 12 months up to 3 years. General linear regression and mixed effects models were employed. RESULTS: IADL impairment was associated with the interactions between lower inferior temporal cortical thickness and diagnosis (p < 0.0001), greater lateral occipital cortical thickness and diagnosis (p < 0.0001), and greater amyloid-β 1-42 (Aβ1-42) and diagnosis (p = 0.0002) at baseline (driven by AD dementia). Lower baseline supramarginal (p = 0.02) and inferior temporal (p = 0.05) cortical thickness, lower Aβ1-42 (p < 0.0001), and greater total tau (t-tau) (p = 0.02) were associated with greater rate of IADL impairment over time. CONCLUSIONS: Temporal atrophy is associated with IADL impairment in mild AD dementia at baseline, while baseline parietal and temporal atrophy, lower CSF Aβ1-42, and greater t-tau predict worsening IADL impairment over time across the AD spectrum. These results emphasize the importance of assessing IADL at the stage of MCI and even at the transition from CN to MCI.
BACKGROUND: Impairment in instrumental activities of daily living (IADL) heralds the transition from mild cognitive impairment (MCI) to dementia and is a major source of burden for both the patient and caregiver. OBJECTIVE: To investigate the relationship between IADL and regional cortical thinning and cerebrospinal fluid (CSF) Alzheimer's disease (AD) biomarkers cross-sectionally and longitudinally in clinically normal (CN) elderly, MCI, and mild AD dementia subjects. METHODS: Two hundred and twenty nine CN, 395 MCI, and 188 AD dementia subjects participating in the Alzheimer's Disease Neuroimaging Initiative underwent baseline magnetic resonance imaging, baseline lumbar puncture, and clinical assessments, including the Functional Activities Questionnaire used to measure IADL, every 6 to 12 months up to 3 years. General linear regression and mixed effects models were employed. RESULTS:IADL impairment was associated with the interactions between lower inferior temporal cortical thickness and diagnosis (p < 0.0001), greater lateral occipital cortical thickness and diagnosis (p < 0.0001), and greater amyloid-β 1-42 (Aβ1-42) and diagnosis (p = 0.0002) at baseline (driven by AD dementia). Lower baseline supramarginal (p = 0.02) and inferior temporal (p = 0.05) cortical thickness, lower Aβ1-42 (p < 0.0001), and greater total tau (t-tau) (p = 0.02) were associated with greater rate of IADL impairment over time. CONCLUSIONS:Temporal atrophy is associated with IADL impairment in mild AD dementia at baseline, while baseline parietal and temporal atrophy, lower CSF Aβ1-42, and greater t-tau predict worsening IADL impairment over time across the AD spectrum. These results emphasize the importance of assessing IADL at the stage of MCI and even at the transition from CN to MCI.
Entities:
Keywords:
Alzheimer's disease; cerebrospinal fluid; instrumental activities of daily living; magnetic resonance imaging; mild cognitive impairment
Authors: Anne M Fagan; Mark A Mintun; Robert H Mach; Sang-Yoon Lee; Carmen S Dence; Aarti R Shah; Gina N LaRossa; Michael L Spinner; William E Klunk; Chester A Mathis; Steven T DeKosky; John C Morris; David M Holtzman Journal: Ann Neurol Date: 2006-03 Impact factor: 10.422
Authors: R Nitrini; P Caramelli; E Herrera; V S Bahia; L F Caixeta; M Radanovic; R Anghinah; H Charchat-Fichman; C S Porto; M T Carthery; A P J Hartmann; N Huang; J Smid; E P Lima; L T Takada; D Y Takahashi Journal: Alzheimer Dis Assoc Disord Date: 2004 Oct-Dec Impact factor: 2.703
Authors: M H Tabert; S M Albert; L Borukhova-Milov; Y Camacho; G Pelton; X Liu; Y Stern; D P Devanand Journal: Neurology Date: 2002-03-12 Impact factor: 9.910
Authors: E Salmon; S Lespagnard; P Marique; F Peeters; K Herholz; D Perani; V Holthoff; E Kalbe; D Anchisi; S Adam; F Collette; G Garraux Journal: J Neurol Date: 2005-02-23 Impact factor: 4.849
Authors: Annika Olsson; Hugo Vanderstichele; Niels Andreasen; Geert De Meyer; Anders Wallin; Björn Holmberg; Lars Rosengren; Eugeen Vanmechelen; Kaj Blennow Journal: Clin Chem Date: 2004-11-24 Impact factor: 8.327
Authors: Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski Journal: Ann Neurol Date: 2009-04 Impact factor: 10.422
Authors: Rachel L Nosheny; Monica R Camacho; Chengshi Jin; John Neuhaus; Diana Truran; Derek Flenniken; Miriam Ashford; Maria C Carrillo; Keith N Fargo; James Hendrix; Lucy Hanna; Gil Rabinovici; Paul Maruff; R Scott Mackin; Michael W Weiner Journal: Alzheimers Dement Date: 2020-07-27 Impact factor: 21.566
Authors: Maria Vassilaki; Jeremiah A Aakre; Walter K Kremers; Michelle M Mielke; Yonas E Geda; Mary M Machulda; David S Knopman; Preciosa M Coloma; Barbara Schauble; Prashanthi Vemuri; Val J Lowe; Clifford R Jack; Ronald C Petersen; Rosebud O Roberts Journal: J Am Geriatr Soc Date: 2018-11-21 Impact factor: 5.562
Authors: Gad A Marshall; Amy S Zoller; Kathleen E Kelly; Rebecca E Amariglio; Joseph J Locascio; Keith A Johnson; Reisa A Sperling; Dorene M Rentz Journal: Curr Alzheimer Res Date: 2014 Impact factor: 3.498
Authors: Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; John C Morris; Ronald C Petersen; Andrew J Saykin; Leslie M Shaw; Arthur W Toga; John Q Trojanowski Journal: Alzheimers Dement Date: 2017-03-22 Impact factor: 21.566
Authors: Amy S Zoller; Ildiko M Gaal; Christine A Royer; Joseph J Locascio; Rebecca E Amariglio; Deborah Blacker; Olivia I Okereke; Keith A Johnson; Reisa A Sperling; Dorene M Rentz; Gad A Marshall Journal: Curr Alzheimer Res Date: 2014 Impact factor: 3.498
Authors: Gad A Marshall; Jennifer R Gatchel; Nancy J Donovan; Martha C Muniz; Aaron P Schultz; J Alex Becker; Jasmeer P Chhatwal; Bernard J Hanseeuw; Kathryn V Papp; Rebecca E Amariglio; Dorene M Rentz; Reisa A Sperling; Keith A Johnson Journal: J Alzheimers Dis Date: 2019 Impact factor: 4.472
Authors: Bernard J Hanseeuw; Aaron P Schultz; Rebecca A Betensky; Reisa A Sperling; Keith A Johnson Journal: Alzheimers Dement Date: 2016-07-13 Impact factor: 21.566